Recruiting Patients with Primary Diffuse Large B-Cell Lymphoma A double-blind, randomized, international multicenter phase III study for patients with newly diagnosed diffuse large B-cell lymphoma has been approved by the State Food and Drug Administration and will enroll 800 subjects worldwide. Patients who are screened and qualified will receive free R-CHOP background dosing and trial medication, and will receive all tests specified in the protocol at no cost. If you are surrounded by patients who meet the following conditions and are able to undergo treatment, return visits and examinations as requested by your doctor You can contact us: ・Male or female 18 years of age or older ・Newly diagnosed diffuse large B-cell lymphoma with good physical status ・Stage II, III or IV clinical stage ・No previous treatment for diffuse large B-cell lymphoma.